EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2024
Defining high bleeding risk in patients undergoing transcatheter aortic valve implantation: a VARC-HBR consensus document.
СтатьяConsensus StatementНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Garot Philippe, Morice Marie-Claude, Angiolillo Dominick J, Cabau Josep Rodés-, Park Duk-Woo, Van Mieghem Nicolas M, Collet Jean-Philippe, Leon Martin B, Sengottuvelu Gunasekaran, Neylon Antoinette, Ten Berg Jurrien M, Mylotte Darren, Tchétché Didier, Krucoff Mitchell W, Reardon Michael J, Piazza Nicolo, Mack Michael J, Généreux Philippe, Makkar Raj, Hayashida Kentaro, Ohno Yohei, Mochizuki Shuichi, Shirai Yuko, Matsumara Ryosuke, Jin Yu, Webb John G, Cutlip Donald E, Chen Mao, Spitzer Ernest, Mehran Roxana, Capodanno Davide
Аннотация
<span style="font-size:12pt"><span style="font-family:Aptos,sans-serif">The identification and management of patients at high bleeding risk (HBR) undergoing transcatheter aortic valve implantation (TAVI) are of major importance, but the lack of standardised definitions is challenging for trial design, data interpretation, and clinical decision-making. The Valve Academic Research Consortium for High Bleeding Risk (VARC-HBR) is a collaboration among leading research organisations, regulatory authorities, and physician-scientists from Europe, the USA, and Asia, with a major focus on TAVI-related bleeding. VARC-HBR is an initiative of the CERC (Cardiovascular European Research Center), aiming to develop a consensus definition of TAVI patients at HBR, based on a systematic review of the available evidence, to provide consistency for future clinical trials, clinical decision-making, and regulatory review. This document represents the first pragmatic approach to a consistent definition of HBR evaluating the safety and effectiveness of procedures, devices and drug regimens for patients undergoing TAVI.</span></span>.